نتائج البحث - Peter Slasor

  • يعرض 1 - 9 نتائج من 9
تنقيح النتائج
  1. 1
    Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

    Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis حسب Lawrence Jacobs, Roy W. Beck, Jack H. Simon, R. Phillip Kinkel, Carol M. Brownscheidle, T. J. Murray, Nancy A. Simonian, Peter Slasor, Alfred Sandrock

    منشور في 2000
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa

    Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa حسب Angela Schulz, Christoph Schwering, Eva Wibbeler, Lena Marie Westermann, Luca Hagenah, Susanne Lezius, Ashok Kumar Jha, Abigail Hunt, Peter Slasor, Pascal Reisewitz, Miriam Nickel

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Study of Intraventricular Cerliponase Alfa for CLN2 Disease

    Study of Intraventricular Cerliponase Alfa for CLN2 Disease حسب Angela Schulz, Temitayo Ajayi, Nicola Specchio, Emily de los Reyes, Paul Gissen, Douglas Ballon, Jonathan P. Dyke, Heather Cahan, Peter Slasor, David Jacoby, Alfried Kohlschütter

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study

    Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study حسب Christian J. Hendriksz, Barbara K. Burton, Thomas R. Fleming, Paul Harmatz, Derralynn Hughes, Simon Jones, Hsiang‐Yu Lin, Eugen Mengel, Maurizio Scarpa, Vassili Valayannopoulos, Roberto Giugliani, Peter Slasor, Debra L. Lounsbury, Wolfgang Dummer

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study

    Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study حسب Miriam Nickel, Alessandro Simonati, David Jacoby, Susanne Lezius, Dirk Kilian, Benjamin Van de Graaf, Odelya E. Pagovich, Barry E. Kosofsky, Kaleb Yohay, Matthew Downs, Peter Slasor, Temitayo Ajayi, Ronald G. Crystal, Alfried Kohlschütter, Dolan Sondhi, Angela Schulz

    منشور في 2018
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects

    The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects حسب Paul Harmatz, Eugen Mengel, Roberto Giugliani, Vassili Valayannopoulos, Shuan-Pei Lin, Rossella Parini, Nathalie Guffon, Barbara K. Burton, Christian J. Hendriksz, John J. Mitchell, Ana María Martins, Simon Jones, Norberto Guelbert, Ashok Vellodi, Carla E. M. Hollak, Peter Slasor, Celeste Decker

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study

    Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study حسب Angela Schulz, Nicola Specchio, Emily de los Reyes, Paul Gissen, Miriam Nickel, Marina Trivisano, Shawn C. Aylward, Anupam Chakrapani, Christoph Schwering, Eva Wibbeler, Lena Marie Westermann, Douglas Ballon, Jonathan P. Dyke, Anu Cherukuri, Shailesh Bondade, Peter Slasor, Jessica Cohen Pfeffer

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome

    Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome حسب Paul Harmatz, Eugen Mengel, Roberto Giugliani, Vassili Valayannopoulos, Shuan-Pei Lin, Rossella Parini, Nathalie Guffon, Barbara K. Burton, Christian J. Hendriksz, John J. Mitchell, Ana María Martins, Simon Jones, Norberto Guelbert, Ashok Vellodi, Frits A. Wijburg, Kehu Yang, Peter Slasor, Celeste Decker

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome

    Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome حسب Christian J. Hendriksz, Rossella Parini, Moeenaldeen AlSayed, Julian Raiman, Roberto Giugliani, Martha Luz Solano Villarreal, John J. Mitchell, Barbara K. Burton, Norberto Guelbert, Fiona Stewart, Derralynn Hughes, Kenneth I. Berger, Peter Slasor, Robert Matousek, Elaina Jurecki, Adam J. Shaywitz, Paul Harmatz

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: